Paterna Angela, Kincses Annamária, Spengler Gabriella, Mulhovo Silva, Molnár Joseph, Ferreira Maria-José U
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Dóm tér 10, H-6720 Szeged, Hungary.
Eur J Med Chem. 2017 Mar 10;128:247-257. doi: 10.1016/j.ejmech.2017.01.044. Epub 2017 Feb 1.
Dregamine (1) and tabernaemontanine (2), two epimeric monoterpene indole alkaloids isolated in large amount from the roots of the African plant Tabernaemontana elegans, were derivatized, yielding ten imine derivatives, as previously described (3-12). In the present study, aiming at increasing the pool of analogues for establishing structure-activity relationships (SAR), compounds 1 and 2 were further submitted to several chemical transformations, yielding thirteen new derivatives (13-25). Their structures were assigned by spectroscopic methods, including 1D and 2D NMR experiments. Compounds 1-25 were evaluated for their effects on the reversion of multidrug resistance (MDR) in cancer cells mediated by P-glycoprotein (P-gp/ABCB1), through combination of functional and chemosensitivity assays, using a human ABCB1-transfected mouse T-lymphoma cell model. SAR analysis showed that different substituents at C-3 and at the indole nitrogen led to different ABCB1 modulatory effects. When compared to the parent compounds, a remarkable enhancement in MDR reversal activity was found for derivatives sharing a new aromatic moiety. Thus, the strongest ability as MDR reversers, and a manifold activity when compared to verapamil, was found for compound 8, the epimeric compounds 9 and 10, and compound 15, bearing pyrazine, bromo-pyridine, and methoxybenzyloxycarbonyl moieties, respectively. In drug combination assays, all compounds tested were revealed to interact synergistically with doxorubicin. Collectively, the results indicate that some of these derivatives may be promising leads for overcoming MDR in cancer.
从非洲植物雅致狗牙花(Tabernaemontana elegans)的根部大量分离得到的两种差向异构单萜吲哚生物碱——德瑞加明(1)和狗牙花碱(2),按照之前描述的方法(3 - 12)进行衍生化反应,得到了十种亚胺衍生物。在本研究中,为了增加用于建立构效关系(SAR)的类似物库,化合物1和2进一步进行了几种化学转化,得到了十三种新衍生物(13 - 25)。通过包括一维和二维核磁共振实验在内的光谱方法确定了它们的结构。使用人ABCB1转染的小鼠T淋巴瘤细胞模型,通过功能测定和化学敏感性测定相结合的方法,评估了化合物1 - 25对P - 糖蛋白(P - gp/ABCB1)介导的癌细胞多药耐药性(MDR)逆转的影响。构效关系分析表明,C - 3和吲哚氮上的不同取代基导致不同的ABCB1调节作用。与母体化合物相比,具有新芳香部分的衍生物在MDR逆转活性方面有显著增强。因此,发现化合物8、差向异构体化合物9和10以及分别带有吡嗪、溴吡啶和甲氧基苄氧基羰基部分的化合物15作为MDR逆转剂的能力最强,与维拉帕米相比具有多种活性。在药物联合测定中,所有测试化合物均显示与阿霉素具有协同相互作用。总体而言,结果表明这些衍生物中的一些可能是克服癌症中MDR的有前景的先导化合物。